CAPR Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (17 May 2024 @ 16:00):

Stats
Today's Volume	754 213
Average Volume	356 357
Market Cap	197.23M
EPS	$0 ( 2024-05-13 )
Next earnings date	( $-0.340 ) 2024-08-05
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-7.47
ATR14	$0.00800 (0.13%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-23	Collier Earl M Jr	Buy	30 000	Common Stock
2024-04-23	Collier Earl M Jr	Sell	30 000	Stock Option (Right to Buy)
2024-04-23	Musket David B	Buy	16 156	Common Stock
2024-04-23	Musket David B	Sell	5 750	Stock Option (Right to Buy)
2024-01-02	Kelliher Mike	Buy	30 000	Stock Option (Right to Buy)

INSIDER POWER
79.14
Last 97 transactions
Buy: 2 824 525 \| Sell: 392 146

Volume Correlation

Long: -0.38 (neutral)

Short: -0.86 (strong negative)

Signal:(46.188) Neutral

Capricor Therapeutics Inc Correlation

10 Most Positive Correlations
GLSI	0.907
SUPN	0.898
COIN	0.896
LZ	0.892
GRMN	0.892
MNKD	0.887
IBUY	0.886
OKTA	0.886
OPRA	0.881
MSTR	0.881

10 Most Negative Correlations
BOWX	-0.869
WAVS	-0.859
METX	-0.85
SOFO	-0.837
NERV	-0.825
LMST	-0.823
NVEI	-0.82
ASRVP	-0.819
VERO	-0.816

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Capricor Therapeutics Inc Correlation - Currency/Commodity

0.03
( neutral )

-0.09
( neutral )

0.00
( neutral )

0.02
( neutral )

-0.29
( neutral )

-0.39
( neutral )

Capricor Therapeutics Inc Financials

Annual	2023
Revenue:	$25.18M
Gross Profit:	$24.11M (95.75 %)
EPS:	$-0.830

FY	2023
Revenue:	$25.18M
Gross Profit:	$24.11M (95.75 %)
EPS:	$-0.830

FY	2022
Revenue:	$2.55M
Gross Profit:	$1.85M (72.74 %)
EPS:	$-1.180

FY	2021
Revenue:	$245.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-0.000867

Financial Reports:

No articles found.

Capricor Therapeutics Inc Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Capricor Therapeutics Inc

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); and CAP-1002, which is in Phase II clinical trial for the treatment of cytokine storm associated with SARS-CoV-2. The company also develops CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions; and two vaccine candidates, which are in development stage for the potential prevention of COVID-19. It collaborates with Lonza Houston, Inc. for the clinical manufacturing of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in San Diego, California.